Business Wire

IMPROVE

28.9.2021 14:03:13 CEST | Business Wire | Press release

Share
To Support European Healthcare Systems Post COVID-19, ImPrOve Experts Call for Improved Perioperative Monitoring to Optimise Patient Safety

The Improving Patient Outcomes (ImPrOve) Think Tank, a group of anaesthetists, surgeons and patient representatives, today launched its European Report to address a serious public health issue – death and serious complication rates in the 30-days after high-risk surgery remain high.i In an effort to improve patient safety and outcomes, the Report calls for better physician training on the latest guidelines, funding for modern digital monitoring, greater use of data from modern technologies in health policies and the right for patients to be involved in dialogue about the management of their procedure.

In Europe, 2.4 million patients undergo high-risk surgery every year.ii,iii Evidence from the UK suggests that 80% of postoperative deaths occur in a 10% sub-population of high-risk patients. If this trend continued at a European level, potentially 192,000 will die in the 30-day period after surgery.i While there are many challenges in high-risk surgery, the most alarming complication for the ImPrOve Think Tank is haemodynamic instability, manifested as drops in blood pressure, and known as IOH.i

During high-risk surgery it is vital that blood continues to flow to organs. IOH is common during surgery under general anaesthesia, occurring in up to 99% of patients.i It has the potential to cause tissue damage in any vital organ, but the heart and kidneys are most affected. Recent studies show associations between IOH and increased risk of acute kidney injury (AKI) and myocardial injury iv,v – the leading cause of post-operative mortality.

Postsurgical patients with AKI and myocardial injury stay longer in hospital, have higher readmission rates, and cost more to care for.iv The subsequent financial impact of this also has a significant impact on European healthcare systems. However, if haemodynamic instability is effectively monitored and prevented, these serious complications can be avoided, and patient outcomes can be significantly improved.

“Our mission is to work collaboratively with patient representatives, clinicians and policy makers to improve perioperative patient safety and experience with the help of advanced haemodynamic monitoring technologies”, commented Professor Olivier Huet, ImPrOve Chair and Professor of Anaesthesia and Intensive Care Medicine. “Major gaps still exist in reducing the risk of complications after high-risk surgery across European hospitals, working together is therefore imperative. All stakeholders need to be onboard so that we can create change and address the calls to action.”

By 2050, it is predicted that 1 in 4 people could be over 65.vi With haemodynamic instability reported as high as 83% in more senior patients,vii the ImPrOve Think Tank believe it will be a likely cause of a significant proportion of modifiable postoperative mortality and morbidity in Europe.

“Patients are often unaware of the risks of not receiving innovative digital monitoring technology, so they may not ask for the best perioperative management”, said Ms Luciana Valente, International Relations Manager at SIHA, Italy, and member of the Think Tank. “It is essential that patients are better informed of the key risks associated with their procedure and aware that the use of innovative digital monitoring, and other actions will be taken to mitigate these risks. The more a patient is invested in a procedure, the better the outcomes will be.”

For further information and to download ‘Improving patient safety: why perioperative care and effective monitoring matters” please visit www.improvethinktank.org

References


i Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C et al . Mortality after surgery in Europe: a 7-day cohort study. Lancet. 2021; Sep 22;380(9847):1059-65. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61148-9/fulltext [accessed July 2021].

ii Preoperative Score to Predict Postoperative Mortality – POSPOM Edward’s Presentation

iii Ghaferi, et al. Variation in Hospital Mortality Associated with Inpatient Surgery. N Engl J Med, 2009.

iv Keuffel EL, Rizzo J, Stevens M, Gunnarsson C, Maheshwari K. Hospital costs associated with intraoperative hypotension among non-cardiac surgical patients in the US: a simulation model. J Med Econ. 2019 Jul;22(7):645-651. Available at: https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1591147 [accessed July 2021]

v Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. Br J Anaesth. 2018 Oct;121(4):706-721. Available at: https://bjanaesthesia.org/article/S0007-0912(18)30376-3/fulltext . [accessed July 2021].

vi United Nations. Ageing. 2019. Available at: https://www.un.org/en/sections/issues-depth/ageing/ [accessed July 2021]

vii Wickham A, Highton D, Martin D, The Pan London Perioperative Audit and Research Network. Care of elderly patients: a prospective audit of the prevalence of hypotension and the use of BIS intraoperatively in 25 hospitals in London. Perioper Med (Lond). 2016; 5: 12. Available at: (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882849/ ) [accessed July 2021].

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release

Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release

Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)

SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release

Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8

NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release

New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi

Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release

The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye